Acumen Pharmaceuticals Presents P-I Trial (INTERCEPT-AD) Results of ACU193 for Early Alzheimer’s Disease at AAIC 2023
Shots:
- The P-I US-based trial consists of SAD & MAD cohorts evaluating ACU193 in 65 patients. The trial met primary & secondary objectives & showed proof of mechanism for ACU193
- Rapid, dose-related, significant amyloid plaque reduction within higher dose cohorts (25% in 60mg/kg, q4w cohort at day 63 & 20% in 25 mg/kg, q2w cohort at day 70), was well-tolerated with no drug-related SAEs & low rate of ARIA-E across all cohorts
- PK results in serum & CSF showed a significant dose proportionality & support monthly dosing, dose-related central target engagement of Toxic AβOs was seen. The company plans to discuss the results with regulators to determine the next steps for the clinical development of ACU193 & determine a timeline for progressing to a P-II/III study
Ref: Globenewswire | Image: Acumen
Related News:- Cognition Therapeutics Reports P-II Study (SEQUEL) Results of CT1812 for Mild-to-Moderate Alzheimer’s Disease in Netherlands
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
